We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App





bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution

By LabMedica International staff writers
Posted on 05 Feb 2024
Print article
Image: The VIDAS KUBE next generation system in the VIDAS immunoassay portfolio is highlighted at Medlab Middle East 2024 (Photo courtesy of bioMérieux)
Image: The VIDAS KUBE next generation system in the VIDAS immunoassay portfolio is highlighted at Medlab Middle East 2024 (Photo courtesy of bioMérieux)

bioMérieux (Marcy l'Etoile, France) is participating in Medlab Middle East 2024 as a Diamond Partner where the company is sharing its game-changing innovations. Visitors to the bioMérieux booth can discover, and exchange insights on antimicrobial stewardship, sepsis management, point-of-care solutions, and emergency care, among others.

At Medlab Middle East 2024, bioMérieux is presenting its recently launched VIDAS KUBE, the advanced generation of its VIDAS immunoassay solution which has been trusted by labs around the world for more than 30 years. VIDAS has transformed the field of immunoassays offering laboratories universal access to a simple, automated, and robust technology providing fast and reliable results. Featuring a single-test concept in an all-in-one kit, VIDAS is currently used in more than 160 countries by 25,000 laboratories. It is still one of the most widely used immunoassay systems in clinical laboratories worldwide. VIDAS KUBE, the latest addition to this innovative range, combines advanced technology with the recognized values of the VIDAS solution. The new VIDAS KUBE features a stackable and modular benchtop design and easy implementation that will benefit clinical diagnostic labs. It is compatible with the existing broad routine test menu covering emergency and critical care, immunochemistry, and infectious diseases.

In addition, bioMérieux is showcasing VITEK MS PRIME, a next-level automated MALDI-TOF Mass Spectrometry system that enables accurate microbial identification to the species level. This benchtop high-throughput automated identification system has a robust database, which includes intra-species diversity, and delivers fast and confident microbial identification. The system has the features required to ensure compliance, and you can rely on our validation experts to implement this solution quickly and efficiently. bioMérieux is also highlighting the VITEK REVEAL rapid Antimicrobial Susceptibility Testing, integrated into its Sepsis Solution to help better manage bloodstream infections. Among its point-of-care diagnostic solutions, bioMérieux is highlighting the BIOFIRE SPOTFIRE System which is the latest advancement in molecular infectious disease diagnostics. All of the company’s expertise and cutting-edge FILMARRAY technology are at the heart of the system design. Within its point-of-care respiratory testing solutions, bioMérieux is spotlighting the BIOFIRE SPOTFIRE Respiratory Panels which offer rapid syndromic PCR tests for a range of common pathogens.

Related Links:
bioMérieux 

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gastrointestinal Infection Test
RIDA QUICK Cryptosporidium/Giardia/Entamoeba Combi Test
New
Cryptosporidium Infection Test
Crypto (Card) Rapid Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
MEDLAB 2024
Copyright © 2000-2025 Globetech Media. All rights reserved.